- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time - The VAN is expected to launch in Q4 2024 SAN DIEGO, Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval Supplement Application for ZYNRELEF® (bupivacaine and meloxicam) extended-release ...

SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgic ...

Heron Therapeutics, Inc., (NASDAQ:HRTX) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Corporate Participants Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President and Chief Financial Officer Kevin Warner - SVP of Medical Affairs Strategy and Engagement Conference Call Participants Brandon Folkes - Rodman & Renshaw Serge Belanger - Needham Clara Dong - Jefferies Carl Byrnes - Northland Capital Markets Operator Thank you for standing by. My name is Jermaine, and I will be ...

| --- | --- | --- | |---------------------------------------|-------|-------| | | | | | | | | | Heron Therapeutics Q2 Earnings Call | | | | August 6, 2024 | | | Forward-looking Statements and non-GAAP Disclosures This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forwardlooking statements are based on management's expectations and assumptions as of the date hereof and are subject to certain risks and uncertain ...

Heron Therapeutics (HRTX) reported $36.02 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 13.4%. EPS of -$0.06 for the same period compares to -$0.35 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $35.35 million, representing a surprise of +1.91%. The company delivered an EPS surprise of -50.00%, with the consensus EPS estimate being -$0.04. While investors closely watch year-over-year changes in headline numbers -- revenue and earn ...

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.08 per share when it actually produced a loss of $0.02, delivering a surprise of 75%. Over the last four quarters, the compa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdicti ...

Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance • Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023 • ZYNRELEF ® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024 • ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act") SAN DIEGO, August 6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a ...

Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023 $108.0 to $116.0 million $107.0 to $111.0 million $(22.0) to $3.0 million $(10.0) to $3.0 million ZYNRELEF® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024 ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act") SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biote ...

SAN DIEGO, July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET to report second quarter 2024 financial results and discuss recent business highlights. The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally. Please provide the operator with the passcode 1737564 to join the con ...